Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Gossamer Bio Investors File Securities Lawsuit Over Alleged Misstatements About Phase 3 Drug Trial
A federal securities lawsuit has been filed against Gossamer Bio, Inc. and its CEO, alleging misleading statements about its Phase 3 PROSERA study for the drug seralutinib. The lawsuit claims that Gossamer concealed known risks related to patient enrollment and an unusual placebo response at Latin American clinical sites, which ultimately led to the drug trial failing to meet its primary endpoint and caused the company’s stock to plummet over 80%. Investors who purchased Gossamer securities during the class period of June 16, 2025, through February 20, 2026, and incurred losses may have been directly affected by the alleged misconduct.